{"url_path":"/sec/vbio/8-k/2026-07-14/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-14","source_url":"https://www.sec.gov/Archives/edgar/data/1787740/0001683168-26-005497-index.html","accession_number":"0001683168-26-005497","cik":"0001787740","ticker":"VBIO","issuer_name":"Valion Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1787740/0001683168-26-005497-index.html","primary_entity_key":"0001787740","primary_entity_name":"Valion Bio, Inc."},"word_count":119,"has_tables":true,"body_markdown":"**Item 7.01.  Regulation FD Disclosure.**\n\n** **\n\nOn July 14, 2026, Valion Bio, Inc. (the \"Company\")\nissued a press release providing a business update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on\nForm 8-K.\n\n \n\nThe information in this Item 7.01, including Exhibit\n99.1, is being furnished and shall not be deemed \"filed\" for purposes of Section 18 of the Securities Exchange Act of 1934,\nas amended (the \"Exchange Act\"), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated\nby reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific\nreference in such a filing."}